BAVARIAN NORDIC WKN: 917165 ISIN: DK0015998017 Kürzel: 0DPB Forum: Aktien Thema: Hauptdiskussion

Dip war gestern bei unter 23€....🤷‍♂

Die wir gesehen haben

Wie läuft emergent??

Abwarten i buy the dip

Ja bei meine vorhergesagte 22

Weil man nicht eingestiegen ist🤣🤣🤣

Nicht morgen Freitag

Und morgen wird wieder geheult ;)

Kurs, 26,80€😉

Völlig zurecht. Es ist hier ja auch noch massig Luft nach oben. Die 50€ ist meine erste Zielmarke. Dann sollten wir nach kurzer Konsolidierung die 80€ in Angriff nehmen. Ja nach Verlauf der Infektionen sind dann auch dreistellige Kurse möglich.

Bavarian ist seit 5 Minuten Top1 Beste Performer am Trade Republic 🚀

SUPER die nächste Sau wird durch das Dorf getrieben......bin gespannt wer als erstes heult 😁😂🎈🧦🥂

= Es kommt mehr neu-Kunden. Schon heute?

„Bavarian Nordic is currently in dialogue with several other governments concerning supply of the vaccine to mitigate the current monkeypox outbreak and to explore opportunities for longer term collaboration to build stockpiles for future preparedness. Officially, monkeypox cases have been reported in more than 15 countries as of to-date with numbers continuing to rise. In this unprecedented situation, the Company is making every possible effort to ensure sufficient availability of vaccines to meet the current demand. Paul Chaplin, President and CEO of Bavarian Nordic said: “The current monkeypox outbreak, which is now affecting countries globally, calls for a swift and coordinated response from health authorities, and we are pleased to assist another country with supply of vaccines to fulfil a growing demand. Building on our vast experience and relations with governments in the procurement of vaccines for their national preparedness, we have rapidly adapted to this unprecedented situation and are working closely with other governments to make vaccines available as fast as possible to mitigate the situation.” As a consequence of this order, and improved exchange USD/DKK rates among others, Bavarian Nordic raises its expectations for the financial result for 2022 with revenue now expected to be between DKK 1,300 and 1,500 million (previously between DKK 1,100 and 1,400 million), EBITDA expectations raised to a loss between DKK 1,000 and 1,200 million (previously a loss between DKK 1,000 and 1,300 million) and cash and cash equivalents at year-end now between DKK 1,100 and 1,200 million (previously between DKK 1,000 and 1,200 million). The guidance reflects the significant investments in research and development being made in 2022 to advance the Company’s two lead product candidates: a vaccine against respiratory syncytial virus (RSV) and a booster vaccine against COVID-19 into Phase 3 clinical trials.“

Affenpocken Aktie Nr 1 🇩🇰🇩🇪 Deutschland und Dänemark rettet die Welt. We can Meds. Remember Charité and BioNTech 🚀🧠🏆 #monkeypox

Hier steht man ja erst ganz am Anfang. Erstmal wird der Abverkauf der letzten Monate wieder aufgeholt.